MediWound to Present New EscharEx Data at Leading Wound Care Conferences
Those Who Invested in MediWound (NASDAQ:MDWD) Five Years Ago Are up 30%
MediWound | 6-K: Report of foreign private issuer (related to financial reporting)
Optimistic Buy Rating for Mediwound: Strong Financials and Strategic Growth Initiatives Highlight Promising Future
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Craig-Hallum Maintains MediWound(MDWD.US) With Buy Rating, Announces Target Price $39
Mediwound (MDWD) Receives a New Rating From Craig-Hallum
Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term
MediWound Analyst Ratings
MediWound Reports 2024 Financials and Strategic Advances
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Express News | Mediwound Ltd: Files for Offering of 1.3 Mln of Ordinary Shares by the Selling Shareholder - SEC Filing
Express News | Mediwound Ltd: Files for Mixed Shelf Offering of up to $125 Mln - SEC Filing
Positive Outlook for Mediwound: Buy Rating Driven by Strong NexoBrid Momentum and Robust Pipeline
Earnings Call Summary | MediWound(MDWD.US) Q4 2024 Earnings Conference
MediWound Shares Rise as Q4 Loss Is Narrower Than Expected
Wall Street Awaits Fed Rate Decision as US Equity Futures Waver Pre-Bell
MediWound Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results and Issued FY25 Sales Guidance Above Estimates.
Earnings Preview: MediWound to Report Financial Results on March 19
Top Premarket Gainers